Next Phase Newsletter

A healthcare and technology focused venture capital fund based in USA an Europe only makes equity investments into private companies and has no specific preference in the investment stage. The firm primarily invests in companies that are based in the United States, China, Japan, India, and Europe. The firm is actively seeking new investment opportunities.

The firm is currently looking for new investment opportunities in Biopharmaceutical, Therapeutics and Diagnostics, Medtech, R&D services, and Healthcare IT. Generally the firm invests 65% in Therapeutics, 15%-20% into Medtech/Diagnostics and 15%-20% into HIT/Sevices.

The firm highly prefers to invest in companies with a strong and experienced management team. However, the firm is flexible within specific cases. The firm works with their portfolio companies together to create value for patients and providers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate investment group that invests strategically on behalf of their parent company uses a variety of structures to work with early stage medical technology companies, including both licensing relationships and equity investments on a case by case basis. The firm is a flexible investor, and the firm’s allocation sizes are wide ranging. The firm invests worldwide.

The firm invests in sectors that are relevant to the parent company’s business groups: Cardiovascular, Restorative Therapies (including spinal implants, neuromodulation treatments for pain and urological disorders, deep brain stimulation, and neurovascular devices), Diabetes, and Minimally Invasive Therapies (including general surgery, gastrointestinal care, pulmonology, and respiratory care and monitoring technologies). The firm is interested in diversifying the parent company’s product and services offerings within all of these groups and also in integrating new fields of information technology and services into the strategic areas, such as IT-enabled patient monitoring and contract management of provider facilities. The firm invests at a range of development stages but generally prefers to work with companies that have obtained clinical data regarding their asset.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm actively funds, supports and advances life science technologies from early development through clinical proof-of-concept. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The firm has access to capital to support companies from seed investment through Series A and B financings and the size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the firm can invest directly as a Series A investment along with participation in related Series B investments. The firm is open to global opportunities.

The firm supports opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, the firm is open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly and supportive of first-time CEOs, the firm works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm invests the capital of a small cohort of high-net-worth individuals.  The fund makes growth-stage investments in the healthcare sector, with a highly varied rate and size of allocations. The firm is interested in investment opportunities in North America, Europe and the Middle East.

The firm primarily invests in healthcare services and avoids opportunities that involve scientific or regulatory risk.  The fund is interested in approved medical devices and healthcare supplier/engineering companies that have products on the market; healthcare IT, and connected devices/connected hospital hardware are particularly of interest. The firm does not invest in drug development or biotech R&D companies.

The firm only invests in companies with revenues and indications of market adoption; the fund has no lower bar for revenue rates but will not fund initial batches of a product, as the firm requires data on market receptivity.  The fund invests with a 5-10 year horizon and is therefore interested in long-term growth opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.